Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.69M | -9.47M | 32.69M | 23.40M | 5.80M |
| Total Depreciation and Amortization | 128.00K | 350.00K | 2.12M | 2.17M | 4.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.57M | 6.62M | 18.99M | 29.88M | 36.66M |
| Change in Net Operating Assets | -9.90M | -23.38M | -104.74M | -125.17M | -110.73M |
| Cash from Operations | -21.90M | -25.88M | -50.94M | -69.71M | -63.92M |
| Capital Expenditure | -- | -- | -- | -90.00K | -90.00K |
| Sale of Property, Plant, and Equipment | 599.00K | 948.00K | 948.00K | 393.00K | 349.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.21M | 1.00K | 17.20M | 12.78M | -1.42M |
| Cash from Investing | -607.00K | 949.00K | 18.15M | 13.08M | -1.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -250.00K | -485.00K | -682.00K |
| Issuance of Common Stock | 24.12M | 19.30M | 16.35M | 52.23M | 50.72M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.30M | -1.00K | -1.00K | -35.97M | 480.00K |
| Cash from Financing | 8.82M | 19.30M | 16.10M | 15.77M | 50.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.68M | -5.63M | -16.69M | -40.86M | -14.56M |